Edward Nash
Stock Analyst at Canaccord Genuity
(4.54)
# 274
Out of 5,005 analysts
88
Total ratings
55.56%
Success rate
24.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $7.29 | +284.09% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $6.53 | +206.28% | 3 | Sep 30, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $140 | $88.15 | +58.82% | 10 | Sep 25, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $26.41 | +134.76% | 3 | Sep 17, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $428 → $526 | $443.01 | +18.73% | 11 | Sep 12, 2025 | |
| VRNA Verona Pharma | Downgrades: Hold | $107 | $106.79 | +0.20% | 10 | Jul 9, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $24.64 | +90.75% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.51 | +1,682.18% | 2 | Feb 26, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.52 | +163.16% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $46.10 | +58.35% | 6 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $39.88 | +123.17% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $14 | $3.60 | +288.89% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.07 | +647.66% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $9.10 | +86.81% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.44 | -18.03% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.57 | +11,364.97% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $31.21 | +162.74% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $5.39 | +1,384.23% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $54.92 | -12.60% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.41 | +11,914.79% | 1 | Nov 8, 2017 |
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $7.29
Upside: +284.09%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $6.53
Upside: +206.28%
Corcept Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $140
Current: $88.15
Upside: +58.82%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $26.41
Upside: +134.76%
Madrigal Pharmaceuticals
Sep 12, 2025
Maintains: Buy
Price Target: $428 → $526
Current: $443.01
Upside: +18.73%
Verona Pharma
Jul 9, 2025
Downgrades: Hold
Price Target: $107
Current: $106.79
Upside: +0.20%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $24.64
Upside: +90.75%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.51
Upside: +1,682.18%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.52
Upside: +163.16%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $46.10
Upside: +58.35%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $39.88
Upside: +123.17%
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $3.60
Upside: +288.89%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.07
Upside: +647.66%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $9.10
Upside: +86.81%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.44
Upside: -18.03%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.57
Upside: +11,364.97%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $31.21
Upside: +162.74%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $5.39
Upside: +1,384.23%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $54.92
Upside: -12.60%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.41
Upside: +11,914.79%